Trial Profile
A Phase II Trial of SOM230(PasireotideLAR) and Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary) ; Topotecan (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 18 Aug 2011 New trial record